The nonreceptor, protein-tyrosine kinase Syk is a suppressor of breast cancer progression whose expression is inversely correlated with the invasive behavior of cancer cells. In contrast, Syk has a positive function in murine mammary tumor virus-mediated tumorigenesis. A yeast two-hybrid screen using a library from human mammary gland identified tumor necrosis factor (TNF) receptor-associated factor-interacting protein (TRIP) as an Syk-binding partner. This interaction is mediated by the C-terminal region of TRIP and is enhanced by the treatment of cells with TNF and the tyrosine phosphorylation of Syk. Syk and TRIP have opposing functions in TNF-signaling pathways. Syk enhances the activation of nuclear factor-jB by TNF and this is antagonized by TRIP. The overexpression of TRIP sensitizes cells to TNF-induced apoptosis, an effect that can be reversed by the coexpression of Syk.
Introduction
Syk is a nonreceptor protein-tyrosine kinase that exhibits characteristics of a tumor suppressor to regulate malignant progression in breast cancer. Syk is expressed in normal breast epithelia and breast cancer cells with low tumorigenic potential, but is reduced or absent in more malignant and highly invasive tumor cells (Coopman et al., 2000; Toyama et al., 2003; Moroni et al., 2004) . Decreased expression of Syk is correlated with poor prognosis and increased risk of distant metastases in patients (Toyama et al., 2003) . On the other hand, the inappropriate activation of Syk in breast epithelial cells by the expression of proteins containing immunoreceptor tyrosine-based activation motifs (ITAMs) can be a positive event in the initiation of tumorigenesis (Katz et al., 2005) . Thus, it will be important to understand the nature of the pathways in which Syk participates and the substrates and binding partners with which it interacts in epithelial cells to determine how it can both promote and inhibit the tumorigenic phenotype.
Syk has been best characterized as an element of the signaling apparatus that couples receptors bearing cytoplasmic ITAMs to the regulation of multiple intracellular pathways in hematopoietic cells (Kurosaki, 2000; Latour and Veillette, 2001 ). In addition to ITAM-bearing receptors, Syk also is coupled directly or indirectly to several different classes of receptors, but by mechanisms that are less well defined. One example is the receptor for tumor necrosis factor (TNF) (Takada and Aggarwal, 2004; Eliopoulos et al., 2006) . In Jurkat T cells, TNF stimulates the activity of Syk leading to the activation of nuclear factor-kB (NF-kB) to promote cell survival (Takada and Aggarwal, 2004) . The downregulation of Syk by siRNA inhibits TNF signaling in Jurkat cells and airway epithelial cells (Takada and Aggarwal, 2004; Ulanova et al., 2005) . We have found that Syk in breast epithelial cells also is a positive regulator of TNF signaling.
Because the level at which Syk participates in TNFsignaling pathways has not been well defined, we conducted a yeast two-hybrid screen to search for binding partners known to participate in TNF signaling. In this study, we identified TNF receptor-associated factor (TRAF)-interacting protein (TRIP) as a novel Syk-binding partner. TRIP is a 53 kDa protein that contains an N-terminal RING finger, coiled-coil and leucine zipper regions that bind TRAF-family proteins (Lee et al., 1997; Besse et al., 2007) and a largely disordered C-terminal half reported to interact with CYLD, a ubiquitin hydrolase (Regamey et al., 2003 ). Here we demonstrate that in MCF7 breast cancer cells, Syk and TRIP interact with one another and have opposing effects on TNF signaling. These studies provide an important clue as to one mechanism by which Syk participates in the regulation of cell growth and survival in breast epithelial cells.
Results

TRIP and Syk interact in a yeast two-hybrid assay
To search for Syk-interacting proteins, we screened a cDNA library from normal human mammary gland using a yeast two-hybrid approach with Syk as bait. Three independent cDNA clones were identified that encoded full-length TRIP. Neither the N-terminal half (aa 1-271) nor the coiled-coil plus leucine zipper domains of TRIP were capable of interacting with Syk ( Figure 1a ). The N-terminal RING finger (aa 1-51) could be eliminated without disrupting the interaction. The C-terminal half of TRIP alone (aa 271-469) was sufficient for binding. However, under the most stringent screening conditions, a region (aa 51-271) within the N-terminal half also was needed for an optimal interaction. TRIP interacted with both wildtype Syk and catalytically inactive Syk(K396R) under low stringency selection conditions (Figure 1b) . However, under highly stringent conditions, TRIP interacted only with active Syk. Neither the tandem pair of SH2 domains nor the kinase domain bound to TRIP. The preferential binding of TRIP to active Syk suggests a function for tyrosine phosphorylation in promoting an optimal interaction.
Syk and TRIP interact in coimmunoprecipitation and pull-down assays Immobilized glutathione S-transferase (GST)-Syk was able to bind and recover transiently expressed Myc-TRIP from MCF7(BD) cell lysates ( Figure 2a ). MCF7(BD) are MCF7 cells that lack endogenous Syk (see below). This interaction was moderately enhanced by the autophosphorylation of GST-Syk. Similarly, Myc-TRIP and Syk-EGFP (enhanced green fluorescent protein) could be coimmunoprecipitated by anti-GFP antibodies from lysates of MCF7(BD) cells transiently expressing both proteins (Figure 2b ). Syk is phosphorylated rapidly following the treatment of Jurkat cells and macrophages with TNF (Takada and Aggarwal, 2004; Eliopoulos et al., 2006) . The phosphorylation of Syk-EGFP also was transiently enhanced in MCF7(BD) cells treated with TNF ( Figure 2c ). This correlated with an increase in the interaction of Myc-TRIP with Syk-GFP as measured by coimmunoprecipitation ( Figure 2b ). This is consistent with a function for tyrosine phosphorylation in enhancing the interaction between Syk and TRIP.
Syk and TRIP interact in the detergent-insoluble fraction When TRIP or Myc-TRIP was expressed in MCF7(BD) cells, a major portion of each was insoluble in detergent lysis buffer whereas the majority of expressed Syk-EGFP was soluble (Figure 3a) . Considerably more Syk-EGFP was present in the detergent-insoluble fraction of cells that also expressed exogenous TRIP. A portion of Syk-EGFP in this fraction exhibited a slower electrophoretic mobility characteristic of Syk when it is phosphorylated on tyrosine (Keshvara et al., 1998) . This was confirmed by western blotting with antiphosphotyrosine antibodies (Figure 3a) . Treatment of cells with TNF induced a further increase in the amount of Syk within the insoluble fraction (although the majority of the kinase remained in the soluble fraction). A similar effect was observed when cells were treated with the protein-tyrosine phosphatase inhibitor, pervanadate (Figure 3b ). Unlike Syk-EGFP, catalytically inactive (Supplementary Figure  1a ) remained primarily in the soluble fraction of lysates from cells also expressing TRIP (Figure 3c ). Three linker B tyrosine residues on Syk (Y317, Y342 and Y346) serve as docking sites for proteins containing phosphotyrosine-binding domains. Mutation of Y317 did not affect the relocation of the kinase to the detergent-insoluble fraction (Figure 3d ). However, replacement of both Y342 and Y346 by phenylalanine resulted in a much reduced TRIP-dependent relocalization. These results suggest that phosphotyrosines at 342 and/or 346 promote the interaction of Syk with TRIP.
Syk induces phosphorylation of TRIP on tyrosine
When coexpressed with Syk-EGFP, a fraction of TRIP also migrated on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) with a reduced mobility. This altered mobility was dependent on its coexpression with a catalytically active kinase (Figure 3c ). Similarly, this shift was reduced in cells expressing Syk-EGFP(Y342F/ Y346F), which interacts poorly with TRIP ( Figure 3d ). This result suggested that Syk could catalyse the phosphorylation of TRIP. Consistent with this, a western blot of TRIP immunoprecipitated from MCF7(BD) cells indicated that wild-type Syk-EGFP and Syk-EGFP(Y317F) were able to induce the phosphorylation of TRIP whereas the kinase dead version and Syk-EGFP(Y342F/Y346F) failed to do so (Supplementary Figure 1b) . Thus, the ability of Syk mutants to phosphorylate TRIP correlated with their ability to interact with the protein. surface TNFR1 and lacked endogenous caspase 3, which is a characteristic of MCF7 cells (data not shown). We used these cells to explore a function for Syk in TNF signaling. The expression of Syk-EGFP, but not Syk-EGFP(K396R), enhanced the ability of TNF to activate NF-kB (Figure 5b ). Expression of a form of Syk-EGFP lacking the linker B region also failed to enhance TNF signaling (Figure 5b ). Syk-EGFP(Y317F) was active in enhancing the activation of NF-kB whereas Syk-EGFP(Y342F/Y346F) and Syk-EGFP(Y317F/Y342F/ Y346F) exhibited only a marginal effect on TNF signaling. Thus, the ability of Syk to promote NF-kB activation required Y342 and Y346. This enhanced activation of NF-kB by Syk-EGFP was abrogated by the coexpression of exogenous TRIP (Figure 5d) . Similarly, the TNF-stimulated activation of NF-kB in MCF7(ATCC) cells that express endogenous Syk was inhibited by the expression of TRIP (Supplementary Figure 3a) . Thus, Syk and TRIP had opposing effects on the TNF-stimulated activation of NF-kB.
TRIP negatively regulates the TNF-mediated activation of NF-kB To determine if TRIP also affected TNF signaling in the absence of Syk, we expressed TRIP in the Syk-deficient cells and examined the activity of NF-kB. TRIP significantly reduced the basal activity of NF-kB and moderately inhibited the TNF-stimulated activation of NF-kB (Figure 6a ). However, luciferase expression from both the NF-kB and internal control reporter plasmids was reduced significantly by TNF. In TRIP-transfected cells, treatment with TNF led to a dramatic decline in luciferase expressed from a constitutively active promoter (Figure 6b ). This inhibition was independent of the nature of the promoter and was seen with herpes simplex virus thymidine kinase, cytomegalovirus or even a promoterless construct (data not shown). Thus, the expression of exogenous TRIP sensitized cells to a TNFdependent decrease in gene expression, most likely as a result of its ability to decrease the level of active NF-kB-an important survival factor-and the subsequent loss of transfected cells. Consistent with this hypothesis, overexpression of TRIP correlated with a loss of viable, adherent cells in response to treatment with TNF (Supplementary Figure 3b) . Furthermore, transfection of cells with siRNA to reduce the level of endogenous TRIP resulted in increased DNA binding of NF-kB in response to TNF (Figure 6d ) and decreased TNF-induced activation of caspase 8 (Supplementary Figure 3c) . The expression of exogenous Syk protected cells from the inhibitory effects of TRIP on cell survival following treatment with TNF (Figure 6c ). 
Discussion
Because of the initial characterization of Syk as a potential tumor suppressor, several mechanisms have been proposed to explain how the kinase regulates the growth and proliferation of breast epithelial cells including maintenance of centrosomal function and suppression of transcription (Wang et al., 2005; Zyss et al., 2005) . How Syk participates in signal transduction pathways triggered by extracellular modulators of cell growth, however, remains poorly understood. TNF is a particularly interesting cytokine in that it has pleiotropic effects on epithelial cells due to its ability to couple to both cell death and cell survival pathways. For example, TNF is a proliferation and survival factor for primary mammary epithelial cells and an inducer of apoptosis for many mammary tumor cells (Wilson and Balkwill, 2002) . We observed a 2-to 3-fold increase in the activity of an NF-kB-driven reporter by the reexpression of Syk in Syk-deficient MCF7(BD) cells, suggesting that Syk has a positive function in TNF signaling. This result is consistent with other reports of a function for Syk in enhancing the TNF-dependent activation of NF-kB (Takada and Aggarwal, 2004; Ulanova et al., 2005) .
Despite descriptions of connections between Syk and TNF signaling, little is yet known regarding the molecular mechanism or mechanisms by which these occur. We initiated a search for Syk-associated proteins using a yeast two-hybrid screening strategy and identified TRIP as a novel Syk-interacting protein. TRIP is an interesting candidate because it was reported originally as a binding partner of TRAF2, which associates with the liganded TNFR1 as part of a signaling assembly required for the activation of NF-kB and initiation of the survival pathway. Consequently, the overexpression of TRIP through transfection has been reported to inhibit the TNF-mediated activation of NF-kB in HEK293 cells and HeLa cells (Lee et al., 1997; Regamey et al., 2003) . However, in a subsequent study, no effect of TRIP on proximal signaling events initiated by TNF was observed (Besse et al., 2007) . In this study, we did detect an inhibitory effect of exogenously expressed TRIP on the basal activity of NF-kB and on the Syk plus TNF-stimulated activation of NF-kB in breast epithelial cells. However, the level within the signaling pathway where this inhibition occurs has yet to be completely determined. Because activated NF-kB transcription factors rapidly turn on genes that antagonize the initiation of apoptosis, inhibition of the NF-kB branch of the pathway is known to sensitize cells to TNF-induced cell death, which likely explains the ability of overexpressed TRIP to sensitize cells to the inhibitory effects of TNF. However, this inhibitory activity of TRIP can be reversed by the coexpression of Syk, which might inhibit the activity of cytoplasmic TRIP, sequester TRIP from important nucleolar targets or even counter TRIP's inhibitory effects on TRAF and TNF signaling by regulating the activity of alternative components of the pathway.
The opposing functions of Syk and TRIP in the same pathway prompted us to determine if and where they interact within cells. A previous report identified the localization of overexpressed Myc-TRIP as predominantly perinuclear in COS-7 cells (Regamey et al., 2003) . To our surprise, we found that both endogenous TRIP and exogenously overexpressed TRIP are predominantly found in nucleoli in MCF7(BD) and multiple other cell types. Although the majority of TRIP protein is localized to the nucleus, a small portion of TRIP colocalizes with Syk in punctate cytoplasmic structures and this association is increased significantly in response to TNF. The translocation of proteins out of the nucleus to participate in cytoplasmic signaling events is not without precedent. Daxx, for example, is a RING-finger containing protein that exhibits a largely nuclear localization within PML bodies, but translocates to the cytoplasm to bind and activate apoptosis signalregulating kinase 1 and to promote apoptotic pathways initiated by cell surface receptors including Fas and transforming growth factor-b (Salomoni and Khelifi, 2006) . TNF-treatment enhances the coimmunoprecipitation of Syk and TRIP and the translocation of Syk into a detergent-insoluble fraction in TRIP-expressing cells. This increased association correlates with the transient induction of the phosphorylation of Syk on tyrosine following the treatment of cells with TNF. Our yeast two-hybrid and biochemical interaction experiments indicate that the interaction between Syk and TRIP is enhanced by the autophosphorylation of Syk on tyrosine residues. Also, the movement of Syk to the detergent-insoluble fraction of TRIP-expressing cells is dependent on its catalytic activity and phosphorylation on Y342 and Y346. It is interesting to note that kinase activity and phosphorylation on Y342 and Y346 are also necessary for Syk's ability to enhance TNF signaling. The correlation of Syk's effect on NF-kB with its ability to interact and phosphorylate TRIP suggests a functional interplay between these two proteins.
Our results suggest a model in which a receptorapproximate event rapidly induces the tyrosine phosphorylation of Syk following TNF-stimulation in MCF7 cells. A portion of active Syk with phosphorylation on Y342 and/or Y346 interacts with the C-terminal regions of TRIP. The interaction between Syk and TRIP results in the tyrosine phosphorylation of TRIP and also shifts a portion of Syk to a detergent-insoluble fraction, which may represent the Syk associated with TRIP in punctuate protein complexes observed in the cytoplasm. It is possible that Syk, which can shuttle in and out of the nucleus (Zhou et al., 2006) , is responsible for the export of the Syk-TRIP complex to the cytoplasm. However, it is equally possible that it is TRIP that modulates the intracellular localization of Syk. It is not yet known if the Syk-TRIP complex also is associated with TRAF2. Because it has been reported that the N-terminal region of TRIP, but not the C-terminal region where Syk binds, mediates the interaction with TRAF2, it is possible that TRIP may interact with both Syk and TRAF2 simultaneously. Thus, it will be of considerable interest to examine the composition of the punctate complexes observed in the cytoplasm to determine if they also contain TRAF2 and other components of TNF-signaling pathways. Future investigations also will be directed toward understanding how Syk and TRIP modulate the function of one another and how this interaction contributes to the signaling events leading to the activation of NF-kB.
Although an anti-apoptotic function of Syk appears to be contradictory with its proposed function as a tumor suppressor, Syk appears to have more complicated effects on breast epithelial cells than what was perceived originally. Although the enforced expression of Syk in malignant breast cancer cells leads to defective mitosis and cell growth (Coopman et al., 2000) , Syk has a positive function in virus-mediated cellular transformation when it is activated by ITAM-containing viral proteins (Katz et al., 2005; Lu et al., 2006) . Whereas TRIP is expressed in multiple breast epithelial cell lines ranging from nonmalignant MCF10A to highly invasive MDA-MB-231, Syk is reduced in level or is lost from more malignant cells. Because many transformed cells exhibit an enhanced sensitivity toward the pro-apoptotic effects of TNF, it is possible that the absence of Syk contributes to this phenotype by leaving the function of TRIP unchecked.
Materials and methods
Cells and plasmids MCF7 cell lines were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 100 U/ml penicillin Interaction of Syk and TRIP Q Zhou and RL Geahlen and 100 mg/ml streptomycin. For the generation of stable Syk-EGFP-expressing cells, Syk-deficient MCF7(BD) cells were transfected with a plasmid expressing Syk-EGFP and a puromycin resistance gene and selected by treatment with puromycin (1 mg/ml). The series of Syk-EGFP-fusion constructs were described previously (Ma et al., 2001) . The plasmids expressing nontagged TRIP or its truncation mutants were generated by inserting TRIP cDNA or cDNA fragments into the pcDNA4/TO vector (Invitrogen, Carlsbad, CA, USA). Similarly, full-length TRIP cDNA was cloned into the pCMV-Myc vector (BD Biosciences, Franklin Lakes, NJ, USA) for expressing Myc-tagged TRIP. The NF-kB-specific firefly luciferase reporter, pNF-kB-luc, was obtained from Stratagene (La Jolla, CA, USA). The internal control plasmid, pRL-TK, was from Promega (Madison, WI, USA).
Reagents
Primary antibodies against Syk (N19), Myc (9E10), p38, Sp1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The caspase 8 antibody (1C12) was from Cell Signaling Technology (Beverly, MA, USA). Anti-phosphotyrosine (4G10) was from Millipore/Upstate Biotechnology (Bellerica, MA, USA). Anti-GFP was from BD Biosciences. Rodamineconjugated goat anti-rabbit and Alexa Flour 488-conjugated goat anti-mouse secondary antibodies were obtained from Jackson ImmunoResearch Laboratories (West Grove, PA, USA) and Molecular Probes (Eugene, OR, USA), respectively. TNF-a was purchased from R&D Systems (Minneapolis, MN, USA). The N-terminal (aa 1-275) and C-terminal (aa 278-469) halves of TRIP were expressed in bacteria as GST-fusion proteins and used as antigens for the immunization of rabbits (Lampire Biological Laboratories, Pipersville, PA, USA). Anti-TRIP antibodies were affinity-purified using each fusion protein immobilized on glutathione-agarose.
Yeast two-hybrid analyses
Plasmids expressing the Gal4 DNA-binding domain fused to Syk, Syk(K396R) , the tandem SH2 domains or the catalytic domain were constructed using the pGBKT7 vector (Moon et al., 2004) . The human mammary gland cDNA library (Clontech, Palo Alto, CA, USA) was transformed into AH109 cells pretransformed with pGBKT7-Syk. Plasmids were eluted from colonies that grew on stringent selection media, amplified and sequenced. TRIP cDNA or its fragments were cloned into pACT2 for mapping analyses. For interaction assays, AH109 cells were transformed simultaneously with two plasmids expressing wild-type or mutated versions of TRIP and Syk and then tested on selection media with low (Leu GST pull-down and coimmunoprecipitation assays GST-Syk was isolated from Sf9 cell lysates as described (Peters et al., 1996) . Immobilized GST-Syk was autophosphorylated by incubation at 37 1C for 20 min in 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.5, 1 mM ATP, 10 mM MnCl 2 , 1 mM Na 3 VO 4 and 10 mg/ml each of aprotinin and leupeptin. Immobilized proteins were incubated with lysates of MCF7(BD) cells expressing Myc-TRIP and then washed extensively with buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol and 1% NP-40. Bound proteins were eluted in SDS-sample buffer and detected by western blotting. For coimmunoprecipitation experiments, MCF7(BD) cells stably expressing Syk-EGFP were transfected with the Myc-TRIP expression vector and treated with TNF-a (40 ng/ ml) for the indicated time at 37 1C. Cells (5 Â 10 6 ) were lysed in buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol, 0.2% NP-40 and 10 mg/ml each of aprotinin and leupeptin. Anti-GFP immune complexes were separated by SDS-PAGE.
Fluorescence microscopy Cells transfected with Syk-EGFP-or the various TRIPexpression constructs were fixed in 3.7% formaldehyde and then permeabilized with 1% NP-40 for 5 min at room temperature. After washing with phosphate-buffered saline (PBS), cells were incubated with a blocking buffer (10% goat serum in PBS) for 1 h and then with primary (anti-TRIP or anti-Myc) and secondary (rhodamine-labeled goat anti-rabbit IgG or Alexa Fluor 488-labeled goat anti-mouse IgG) antibodies. Cells were washed, stained with 4 0 ,6-diamidino-2-phenylindole (DAPI; Sigma, St Louis, MO, USA) and viewed by fluorescence microscopy.
Cellular fractionation
For fractionations based on detergent solubility, MCF7(BD) cells were lysed in 0.2% NP-40, 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml each of aprotinin and leupeptin and 1 mM Na 3 VO 4 . The detergent-soluble fraction was separated from the insoluble fraction by centrifugation for 5 min at 18 000 g.
Reporter and gel-shift assays for the measurement of NF-kB activity For luciferase-based reporter assays, 3 Â 10 4 MCF7(BD or ATCC) cells were cotransfected using FuGENE 6 (Roche) with the indicated amounts of expression plasmids, 0.2 mg of the pNF-kB-luc reporter plasmid and 0.02 mg of the pRL-TK internal control plasmid. Transfected cells were treated with or without TNF-a for the indicated times. The activities of both luciferases were measured by the Dual Reporter Assay System (Promega). In general, the relative luciferase units represent the NF-kB reporter activities normalized against those of the internal control unless indicated otherwise. For gelshift assays, nuclear extracts (5 mg) from TNF-treated cells were incubated with a 32 P-labeled NF-kB-specific DNA probe (35 fmol) at room temperature for 30 min in a 10 ml reaction containing 10 mM Tris-HCl, pH 8.0, 250 mM KCl, 0.5 mM EDTA, 0.2 mM DTT, 0.1% Triton X-100, 12% glycerol and 1 mg of poly-dI-dC. The 22-mer double-stranded probe was prepared from a sense strand (5 0 -AGT TGA GGG GAC TTT CCC AGG C-3 0 ) and its complementary strand and labeled by T4 kinase. The DNA-protein complexes were separated by 5% native polyacrylamide gel electrophoresis. The radioactive bands were visualized and quantified by a phosphorimager using Optiquant software. The specificity of NF-kB complexes was confirmed by competition assays using the wild-type probe or a probe containing a single nucleotide mutation.
siRNA transfection SmartPool siRNA duplexes against TRIP were obtained from Dharmacon. siRNA (50 nM) was transfected using Lipofectamine 2000. Suppression of TRIP was monitored by immunofluorescence and western blotting.
